


Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Oxford National Institute for Health and Care Research Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴The Royal Marsden Hospital, London, United Kingdom; ⁵Siteman Cancer Center, Washington University, St. Louis, MO, USA; ⁶ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ⁷Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; ⁸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, CA, USA; ⁹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁰Daiichi Sankyo, Basking Ridge, NJ, USA; ¹¹University Hospitals Gasthuisberg & Leuven & KULeuven, Leuven, Belgium

Plain Language Summary



Poster presented at European Society of Medical Oncology Gastrointestinal Cancers Congress 2026; July 1-4, 2026; Munich, Germany, by Eric Van Cutsem
Corresponding author email address: Eric.VanCutsem@kuleuven.be

^aEnrollment of 80 patients was planned; actual enrollment was 79 patients. ^bOther secondary endpoints were ORR, PFS, and DoR by investigator assessment; pharmacokinetics; and anti-drug antibodies.



TEAEs by Preferred Term, n (%)	T-DXd 6.4 mg/kg N = 79	
	Any Grade	Grade ≥3
Nausea	53 (67.1)	6 (7.6)
Vomiting	35 (44.3)	2 (2.5)
Fatigue	33 (41.8)	3 (3.8)
Diarrhea	32 (40.5)	1 (1.3)
Anemia	31 (39.2)	11 (13.9)
Weight decreased	29 (36.7)	4 (5.1)
Decreased appetite	27 (34.2)	4 (5.1)
Constipation	21 (26.6)	0
Alopecia	19 (24.1)	0
Hypokalemia	15 (19.0)	2 (2.5)
Neutrophil count decreased	15 (19.0)	6 (7.6)
Platelet count decreased	15 (19.0)	2 (2.5)
Abdominal pain	14 (17.7)	2 (2.5)
Aspartate aminotransferase increased	14 (17.7)	1 (1.3)
Asthenia	12 (15.2)	1 (1.3)
Blood alkaline phosphatase increased	10 (12.7)	1 (1.3)
Cough	10 (12.7)	1 (1.3)
Neutropenia	10 (12.7)	5 (6.3)
Pyrexia	10 (12.7)	0
COVID-19	9 (11.4)	3 (3.8)
Pneumonitis	9 (11.4)	1 (1.3)
White blood cell count decreased	9 (11.4)	5 (6.3)
Alanine aminotransferase increased	8 (10.1)	1 (1.3)
Back pain	8 (10.1)	0
Dyspnea	8 (10.1)	1 (1.3)
Epistaxis	8 (10.1)	0
Gastroesophageal reflux disease	8 (10.1)	0
Hypoalbuminemia	8 (10.1)	0

1. Uzumampam B et al. *Annc Oncol*. 2023;14:1035-1046.
2. Van Cutsem E et al. *Gastric Cancer*. 2015;18:476-484.
3. Subasinghe T et al. *J Int Med Res*. 2023;51:1-6.
4. Yang Y et al. *Acta Biochim Biophys Sin (Shanghai)*. 2023;55:547-567.
5. ESMO Guidelines Committee. *ESMO guideline on the use of trastuzumab in the treatment of HER2-positive gastric cancer* [prescribing information]. Daiichi Sankyo, Inc.; 2020.
6. Shitara K et al. *N Engl J Med*. 2020;382:2419-2430.
7. Ku Cutsem E et al. *J Cancer Oncol*. 2023;24:744-756.
8. Ku Cutsem E. Presented at: ESMO Congress 2022; September 9-13, 2022; Paris, France.
9. Shitara K et al. *N Engl J Med*. 2023;393:330-348.
10. Daiichi Sankyo, Inc. Press release. January 22, 2024. https://www.daiichisankyo.com/files/news/pressrelease/pdf/2024012201020322_0322_0323.pdf. Accessed May 12, 2024.
11. Daiichi Sankyo, Inc. Press release. March 23, 2020. https://www.daiichisankyo.com/files/news/pressrelease/pdf/20200323020322_0323_0324.pdf. Accessed May 15, 2026.

